Roche's New Drug Shows 22.5% Weight Loss, Challenging Market Leaders

BASEL, SWITZERLAND – January 27, 2026 – Swiss pharmaceutical giant Roche has thrown down the gauntlet in the high-stakes obesity drug market, announcing positive Phase II results for its investigational drug, CT-388. The once-weekly injection achieved a striking 22.5% placebo-adjusted weight loss in participants after 48 weeks, positioning it as a formidable new contender against established blockbusters from Eli Lilly and Novo Nordisk.

The data, from the CT388-103 study, not only showed significant weight reduction but also indicated that participants had not yet reached a weight-loss plateau, suggesting further benefits may be possible with longer treatment. Following the robust results, Roche confirmed it is accelerating the drug into a global Phase III trial program this quarter, a clear signal of its confidence in the asset it acquired in the $2.7 billion takeover of Carmot Therapeutics just last year.

“We are pleased to see such meaningful weight loss in people treated with CT-388,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development, in a company statement. “The robust weight loss combined with a well-tolerated safety profile reinforces our confidence in the clinical development programme as we advance to Phase III trials.”

A New Heavyweight Enters the Ring

CT-388 is a dual-action agonist, targeting both the GLP-1 and GIP hormone receptors, a mechanism it shares with Eli Lilly's highly successful drug Zepbound (tirzepatide). This dual approach has proven more effective for weight loss than targeting the GLP-1 receptor alone, the mechanism used by Novo Nordisk's Wegovy (semaglutide).

While direct, head-to-head trial comparisons are not possible, the 22.5% weight loss figure places CT-388 squarely in the top tier of efficacy. For context, clinical trials for Zepbound showed a mean weight reduction of around 21% at 72 weeks, while Wegovy's trials showed an average loss of 15-17% over 68 weeks. Analysts were quick to note the competitive potential, with one pharmaceutical expert stating the results put CT-388 "roughly in the same ballpark as Lilly's Zepbound."

Beyond the headline number, the Roche trial revealed other impressive metabolic benefits. A remarkable 73% of participants with pre-diabetes at the start of the study achieved normal blood glucose levels after 48 weeks on the highest dose of CT-388, compared to just 7.5% in the placebo group. Furthermore, 54% of participants on that dose saw their Body Mass Index (BMI) fall below 30, the clinical threshold for obesity. The treatment was also well-tolerated, with a low 5.9% discontinuation rate due to adverse events, which were primarily mild-to-moderate gastrointestinal issues consistent with this class of drugs.

Roche believes CT-388 may have a unique advantage due to its design. It employs a "biased signaling" mechanism intended to potently activate the target receptors while minimizing the processes that lead to desensitization. In theory, this could lead to more prolonged and durable pharmacological activity.

The $100 Billion Battle for Weight Loss

The impressive clinical data for CT-388 arrives as the market for obesity medications is exploding, with some analysts forecasting annual sales could exceed $100 billion by the end of the decade. This growth is fueled by a global health crisis; by 2035, more than four billion people—over half the world's population—are projected to be living with excess weight or obesity.

Roche's entry is a calculated, strategic gambit to capture a significant share of this lucrative market. The company has declared its ambition to become a "top three" player in the obesity space, and CT-388 is the cornerstone of that strategy. The company is not just betting on CT-388 as a standalone therapy but is also positioning it as a key component of future combination treatments.

Specifically, Roche plans to pair CT-388 with petrelintide, a long-acting amylin analog from its partnership with Zealand Pharma. Amylin is a different hormone that promotes satiety. The goal of this combination therapy is to potentially achieve even greater weight loss, improve tolerability by mitigating the gastrointestinal side effects common to GLP-1 drugs, and, crucially, preserve lean muscle mass during weight loss—a growing area of focus in obesity treatment. This multi-pronged approach could be a key differentiator for Roche in an increasingly crowded field.

The High Price of Progress

Despite the scientific breakthroughs, the path to widespread patient use is fraught with challenges, primarily centered on cost and access. The current generation of highly effective obesity drugs carries list prices that can exceed $1,000 per month in the United States. This has led to significant hurdles with insurance coverage.

Many health insurers and national payers, including Medicare in the U.S., have been reluctant to provide broad coverage, often classifying these medications as lifestyle or "vanity" drugs rather than essential treatments for a chronic disease. This forces many patients to pay high out-of-pocket costs or forgo treatment altogether, limiting the real-world impact of these medical innovations.

While patient advocacy groups and medical societies are pushing for policy changes to recognize obesity as a chronic disease deserving of full coverage, the debate continues. For Roche and its competitors, navigating this complex reimbursement landscape will be as critical to commercial success as demonstrating clinical efficacy. Even the most effective drug offers no benefit if patients cannot access it. As CT-388 advances into its final phase of testing, its potential to transform both the scales and the standards of care will be watched closely by patients, physicians, and investors alike.